Trial Profile
Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + TC Combination Therapy for Nonresponders to EXE Therapy. (JBCRG-11TC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2021
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Cyclophosphamide; Docetaxel
- Indications Advanced breast cancer; Breast cancer; Early breast cancer
- Focus Therapeutic Use
- 28 Mar 2019 Status changed from active, no longer recruiting to completed.
- 21 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 19 Jun 2014 Planned End Date changed from 30 Sep 2023 to 31 Mar 2026 as reported by University Hospital Medical Information Network - Japan.